Combing Structure-Based Design and Mass Screening to Probe
Ligand Binding to Integrin Receptors
Barry S. Coller M.D.
Vice President for Medical Affairs and Physician-in-Chief
Laboratory of Blood and Vascular Biology
September 26, 2011, Caspary Auditorium, 4 p.m.
Litvinov RI; Barsegov V; Schissler AJ; Fisher AR; Bennett JS; Weisel JW; Shuman H. 2011. Dissociation of bimolecular αIIβ3-fibrinogen complex under a constant tensile force. Biophysical Journal. 100(1):165-73.
Lord MS; Cheng B; McCarthy SJ; et al. 2011. The modulation of platelet adhesion and activation by chitosan through plasma and extracellular matrix proteins. Biomaterials. 32(28):6655-6662 (Request from Markus Library)
Blue R; Li JH; Steinberg J; et al. 2010. Effects of limiting extension at the alpha IIb Genu on ligand binding to integrin alpha IIb beta 2. Journal of Biological Chemistry. 285(23):17604-17613.
Sheldrake HM; Patterson LH. 2009. Function and antagonism of beta(3) integrins in the development of cancer therapy. Current Cancer Drug Targets. 9(4):519-540. (Request from Markus Library)
Basani RB; Zhu H: Thornton MA: et al. 2009. Species differences in small molecule binding to alpha IIb beta 3 are the result of sequence difference in 2 loops of the alpha IIb beta propeller. Blood. 113(4):902-910.
Blue R; Kowalska MA; Hirsch J; et al. 2009. Structural and therapeutic insights from the species specificity and in vivo antithrombotic activity of a novel alpha IIb beta 3 antagonist. Blood 114(1):195-201
Blue R; Murcia M; Karan C; et al. 2008. Application of high-throughput screening to identify a novel alpha IIb-specific small-molecule inhibitor of alpha IIb 3-mediated platelet interaction with fibrinogen. Blood. 111(3):1248-1256.
Hynes, RO. 2002. Integrins: bidirectional, allosteric signaling machines. Cell. 110(6):673-687.